Radiation zaps liver tumors in patients too sick for surgery
NCT ID NCT01899261
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to deliver high-dose radiation directly to the tumor while sparing healthy tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this could offer a non-surgical option to control liver cancer and improve survival for patients who cannot have surgery.
- What could go wrong
- This is a small, early pilot study with only 20 participants, so results may not apply broadly. There is a risk of severe liver, blood, or stomach side effects from radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.